Accolade Named to 2023 Deloitte Technology Fast 500™

Rhea-AI Summary

Accolade (ACCD) Achieves 227% Revenue Growth, Named to Deloitte Technology Fast 500™ List

Positive

• Accolade's 227% revenue growth over the last three years has earned them a spot on the prestigious Deloitte Technology Fast 500™ list, highlighting their exceptional performance in the technology sector.
• Accolade's CEO, Rajeev Singh, attributes the company's success to their unique approach and the dedication of their team, emphasizing the impact of their industry-leading technology on improving health outcomes and lowering costs.

Negative

• None.

Attributes 227% revenue growth to a relentless focus on delivering exceptional outcomes

SEATTLE, Nov. 8, 2023 /PRNewswire/ -- Accolade today announced it has been named to the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29^th year. Accolade grew 227% during this period.

Accolade's chief executive officer, Rajeev Singh, credits a deeply differentiated approach and the dedication of the entire Accolade team with the company's revenue growth. He said, "Accolade is honored to be included in this year's Technology Fast 500 list which recognizes our extraordinary growth over the last three years. Our industry-leading technology enables our physician-led care teams to improve health outcomes, lower costs, and drive engagement. I'm grateful to the 2,200 employees at Accolade for their commitment to our vision of helping every person live their healthiest life."

"Each year we look forward to reviewing the progress and innovations of our Technology Fast 500 winners. This year is especially celebratory as we expand the number of winners to better represent just how many companies are developing new ideas to progress our society and the world, especially during a slow economy," said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. "While software and services and life sciences continue to dominate the top 10, we are encouraged to see other categories making their mark. Congratulations to all the winners who show us how creativity, hard work and perseverance can lead to success."

"As for growing companies, it's always rewarding to be recognized for the ongoing commitment it takes to navigate obstacles, transform when necessary and ultimately create a thriving business," said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte's audit and assurance practice. "Over the nearly 30 years we've been compiling the Technology Fast 500, we've seen new categories emerge, growth rates explode, and certain regional markets shine from the bright talent they attract. We are proud of all the winners for achieving this well-deserved honor."

About the 2023 Deloitte Technology Fast 500
Now in its 29^th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Accolade 
Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan and consumer solutions combine virtual primary care and mental health, expert medical opinion and best-in-class care navigation. These offerings are built on a platform that is engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedIn, Twitter, Instagram and Facebook.

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500^® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they build their future. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's approximately 457,000 people worldwide connect for impact at www.deloitte.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accolade-named-to-2023-deloitte-technology-fast-500-301981929.html

SOURCE Accolade

FAQ

What is the reason for Accolade's inclusion in the Deloitte Technology Fast 500™ list?

Accolade achieved 227% revenue growth over the last three years.

Who is credited for Accolade's revenue growth?

Accolade's CEO, Rajeev Singh, credits the company's success to their unique approach and the dedication of their team.

What does Accolade's industry-leading technology enable their care teams to do?

Accolade's technology enables their physician-led care teams to improve health outcomes, lower costs, and drive engagement.